Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
|Articles|August 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 8
- Volume 4
- Issue 8
Duke, AIS Announce Collaboration To Build Cell Processing Center
DURHAM, NC--Duke University Medical Center and ExVivo Therapies have announced a collaboration to construct and operate a cell processing center, the first on the East Coast. ExVivo is a joint venture between Applied Immune Sciences (AIS) and Rhône-Poulenc Rorer.
Advertisement
DURHAM, NC--Duke University Medical Center and ExVivo Therapieshave announced a collaboration to construct and operate a cellprocessing center, the first on the East Coast. ExVivo is a jointventure between Applied Immune Sciences (AIS) and Rhône-PoulencRorer.
The Durham center, due for completion in late 1995, will processcells to be used in clinical trials of cell and gene therapiesfor certain forms of cancer, AIDS, and other diseases.
Articles in this issue
about 31 years ago
CA 125 Predicts Response to Chemo in Ovarian Caabout 31 years ago
Biochemical Modulation Promising in RT-Resistant GI Cancerabout 31 years ago
Cancer Institute of NJ Adds to its Staffabout 31 years ago
A Century of Breast Cancer Litigation Is 'Deconstructed'about 31 years ago
New Depot Formulation of LHRH Analogue Allows 12-Week Dosingabout 31 years ago
NSABP Investigation Threatens Academic Freedom for All: Fisherabout 31 years ago
Cancer Fax Directory in 3rd Editionabout 31 years ago
HIV-Related Malignancies Increasing, Physicians Tell Panelabout 31 years ago
Breast Cancer Risk Factors Remain Elusive TargetAdvertisement
Related to this article
The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.
Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.
In the phase 3 TANGENT trial, an 8-week course of emactuzumab improved objective response rate vs placebo in patients with tenosynovial giant cell tumor.
In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
2
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
3
Daraxonrasib Demonstrates Consistent Survival Benefit Across Subgroups in Pretreated mPDAC
4
Pembrolizumab Plus Chemo Shows Encouraging Activity in NEPC
5